NIH awards $12.2M for preclinical animal studies, with no fee, over 6 years
Contract Overview
Contract Amount: $12,197,126 ($12.2M)
Contractor: Children's Hospital Corporation, the
Awarding Agency: Department of Health and Human Services
Start Date: 2004-03-31
End Date: 2010-06-30
Contract Duration: 2,282 days
Daily Burn Rate: $5.3K/day
Competition Type: FULL AND OPEN COMPETITION
Number of Offers Received: 2
Pricing Type: COST NO FEE
Sector: R&D
Official Description: PRECLINICAL RESEARCH - ANIMAL STUDIES
Place of Performance
Location: BOSTON, SUFFOLK County, MASSACHUSETTS, 02115
Plain-Language Summary
Department of Health and Human Services obligated $12.2 million to CHILDREN'S HOSPITAL CORPORATION, THE for work described as: PRECLINICAL RESEARCH - ANIMAL STUDIES Key points: 1. Spending focused on R&D, specifically preclinical animal studies. 2. Contract awarded to The Children's Hospital Corporation. 3. Full and open competition was utilized. 4. No fee was associated with this contract.
Value Assessment
Rating: fair
The contract has a 'cost no fee' structure, which can make direct value assessment challenging. The total award of $12.2M over 6 years suggests a significant investment in research.
Cost Per Unit: N/A
Competition Analysis
Competition Level: full-and-open
Full and open competition was employed, indicating a broad search for qualified contractors. This method generally promotes competitive pricing, though the 'cost no fee' structure limits direct price comparison.
Taxpayer Impact: Taxpayer funds are supporting critical preclinical research, with the potential for future medical advancements. The lack of a fee structure means direct profit to the contractor is not a factor.
Public Impact
Supports vital preclinical research for potential medical breakthroughs. Funds are directed towards animal studies, a common stage in drug and treatment development. The long duration (6 years) suggests a sustained research effort.
Waste & Efficiency Indicators
Waste Risk Score: 50 / 10
Warning Flags
- Cost no fee structure makes direct value assessment difficult.
- Limited information on specific research outcomes or milestones.
Positive Signals
- Full and open competition utilized.
- Supports critical R&D in life sciences.
Sector Analysis
This contract falls under Research and Development in the Physical, Engineering, and Life Sciences (NAICS 541710). Spending in this sector is crucial for innovation but can be difficult to benchmark due to the specialized nature of the research.
Small Business Impact
The contractor is The Children's Hospital Corporation, a large entity. There is no indication that small businesses were involved as subcontractors or partners in this specific award.
Oversight & Accountability
The contract was awarded by the National Institutes of Health (NIH), a major research agency within HHS, suggesting established oversight processes for research grants and contracts.
Related Government Programs
- Research and Development in the Physical, Engineering, and Life Sciences
- Department of Health and Human Services Contracting
- National Institutes of Health Programs
Risk Flags
- Potential for research to not yield desired outcomes.
- Long-term nature of research makes immediate value assessment difficult.
- Reliance on animal models may not always translate to human efficacy.
- Complexity of scientific research can obscure performance metrics.
Tags
research-and-development-in-the-physical, department-of-health-and-human-services, ma, dca, 10m-plus
Frequently Asked Questions
What is this federal contract paying for?
Department of Health and Human Services awarded $12.2 million to CHILDREN'S HOSPITAL CORPORATION, THE. PRECLINICAL RESEARCH - ANIMAL STUDIES
Who is the contractor on this award?
The obligated recipient is CHILDREN'S HOSPITAL CORPORATION, THE.
Which agency awarded this contract?
Awarding agency: Department of Health and Human Services (National Institutes of Health).
What is the total obligated amount?
The obligated amount is $12.2 million.
What is the period of performance?
Start: 2004-03-31. End: 2010-06-30.
What specific research questions or therapeutic areas are being addressed by these preclinical animal studies?
The provided data does not specify the exact research questions or therapeutic areas. Preclinical animal studies are a broad category within biomedical research, often preceding human trials for drugs, medical devices, or treatments. Further investigation into NIH funding priorities or specific project descriptions would be needed to identify the precise focus.
How is the success or impact of the research measured under a 'cost no fee' contract?
Success in 'cost no fee' research contracts is typically measured by the achievement of specific research milestones, scientific progress, and the generation of valuable data, rather than direct profit margins. The funding agency, NIH in this case, would likely have performance metrics and review processes to evaluate the scientific merit and progress of the research conducted.
What is the potential long-term return on investment for taxpayers from this $12.2M preclinical research award?
The long-term return on investment is inherently uncertain and speculative, as preclinical research carries significant risk. However, successful outcomes could lead to the development of new therapies, diagnostics, or medical knowledge, potentially improving public health, reducing future healthcare costs, and fostering economic growth through innovation.
Industry Classification
NAICS: Professional, Scientific, and Technical Services › Scientific Research and Development Services › Research and Development in the Physical, Engineering, and Life Sciences
Product/Service Code: RESEARCH AND DEVELOPMENT › AGRICULTURE R&D SERVICES
Competition & Pricing
Extent Competed: FULL AND OPEN COMPETITION
Solicitation ID: RFPNIHNIAIDDAIT0407
Offers Received: 2
Pricing Type: COST NO FEE (S)
Contractor Details
Address: 333 LONGWOOD AVENUE, BOSTON, MA, 90
Business Categories: Category Business, Nonprofit Organization, Not Designated a Small Business, Special Designations, U.S.-Owned Business
Financial Breakdown
Contract Ceiling: $15,404,659
Exercised Options: $12,197,126
Current Obligation: $12,197,126
Timeline
Start Date: 2004-03-31
Current End Date: 2010-06-30
Potential End Date: 2010-06-30 00:00:00
Last Modified: 2013-11-06
More Contracts from Children's Hospital Corporation, the
- Flumed Igf::ot::igf for Other Functions — $31.3M (Department of Health and Human Services)
- Covid-19 & Mis-C VE Study — $24.9M (Department of Health and Human Services)
- Community Finder Platform — $20.4M (Department of Health and Human Services)
- TO Develop Innovative and Safe Multivalent Anti-Opioid Vaccines That Protect Against Heroin and Fentanyl — $19.9M (Department of Health and Human Services)
- Adjuvant Development Program — $13.6M (Department of Health and Human Services)
View all Children's Hospital Corporation, the federal contracts →
Other Department of Health and Human Services Contracts
- Contact Center Operations (CCO) — $5.5B (Maximus Federal Services, Inc.)
- TAS::75 0849::TAS Oper of Govt R&D Goco Facilities — $4.8B (Leidos Biomedical Research Inc)
- THE Purpose of This Contract IS to Provide the Full Complement of Services Necessary to Care for UC in ORR Custody Including Facilities Set-Up, Maintenance, and Support Internal and Perimeter (IF Applicable) Security, Direct Care and Supervision Inc — $3.5B (Rapid Deployment Inc)
- Contact Center Operations — $2.6B (Maximus Federal Services, Inc.)
- Federal Contract — $2.4B (Leidos Biomedical Research Inc)
View all Department of Health and Human Services contracts →